Dana-Farber Cancer Institute/Harvard Cancer Center, Brigham and Women's Hospital and Massachusetts General Hospital is a clinical research site located in Boston, Massachusetts, United States 02115.
Crixeo Health Trust Score: 48/100 (POOR). This profile has not yet been claimed by the site owner.
Dana-Farber Cancer Institute/Harvard Cancer Center, Brigham and Women's Hospital and Massachusetts General Hospital has participated in 1 clinical trials.
Therapeutic areas: Hemoglobinopathies, Anemia, Sickle Cell, Hemoglobin SC Disease.
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID).
Trust Score: 48/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Dana-Farber Cancer Institute/Harvard Cancer Center, Brigham and Women's Hospital and Massachusetts General Hospital has a Crixeo Trust Score of 48/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Dana-Farber Cancer Institute/Harvard Cancer Center, Brigham and Women's Hospital and Massachusetts General Hospital has 1 clinical trials on record. Their work covers Hemoglobinopathies, Anemia, Sickle Cell, Hemoglobin SC Disease.
Dana-Farber Cancer Institute/Harvard Cancer Center, Brigham and Women's Hospital and Massachusetts General Hospital has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.